Turnstone Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Turnstone Biologics, Inc.
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
- Other Names / Subsidiaries
- Myst Therapeutics, Inc.